Palvella Therapeutics PVLA Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Palvella Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Palvella Therapeutics’s 10-Q, filed November 14, 2023, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's free cash flow margin?
- Palvella Therapeutics (PVLA) reported free cash flow margin of -99.8% in Q3 2023.
- How has Palvella Therapeutics's free cash flow margin changed year-over-year?
- Palvella Therapeutics's free cash flow margin increased by 52.1% year-over-year, from -208.2% to -99.8%.
- What is the long-term trend for Palvella Therapeutics's free cash flow margin?
- Over 2 years (2020 to 2022), Palvella Therapeutics's free cash flow margin has grown at a 19.1% compound annual growth rate (CAGR), from -165.8% to -235.4%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.